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INTRODUCTION
Systemic sclerosis (SSc) is a systemic autoimmune disease
of unknown etiology, characterized by microcirculatory dys-
function and accumulation of excessive extracellular matrices.
Among suggested mechanisms, endothelial derangement is
important in the pathogenesis of SSc, resulting in some fea-
tures of vasculopathy such as Raynaud phenomenon and pul-
monary hypertension (1). 
Vascular injury is associated with increased local production
of angiotensin-converting enzyme (ACE) and angiotensin II
(2). ACE is a key enzyme in renin-angiotensin system (RAS)
and widely distributed in human tissues including the lung,
vascular endothelium, kidney, heart, and testes (3). ACE con-
verts angiotensin I to angiotensin II, and inactivates brady-
kinin through the kallikrein-kininogen system. Angiotensin
II may play a role in vascular diseases through vascular smooth
muscle cell contraction and proliferation, monocyte adhesion,
platelet aggregation, mediated either directly or via various
factors such as endothelin, nitric oxide, and prostacyclin (4, 5).
The ACE gene is located in the long arm of chromosome
17 (17q 23), and an insertion/deletion (I/D) polymorphism,
determined by the presence or absence of a 287 base pair (bp)
Alu repeat within intron 16, was identified (6). The DD geno-
type has about two-fold higher serum level of ACE than the
II genotype, and the ID genotype has intermediate level (7).
The DD genotype was associated with endothelial dysfunc-
tion, blunting the stimulated endothelial or donated nitric
oxide response in normal population (8). Some epidemiologic
studies have found that the D allele was associated with in-
creased cardiovascular and renal risk (9).
The association of ACE I/D genes has been studied in other
rheumatic diseases with vascular involvement, and showed
inconsistent data in systemic lupus erythematosus (3, 10),
association of II genotypes in Kawasaki disease with coronary
aneurysm (11), and irrelevance in Korean Behcet’s disease (12).
Although ACE D genotype was reported as a risk factor of
SSc in Italian (13), it has not been evaluated in other ethnic
groups. We studied the association of ACE I/D genotypes
with the development and clinical features of SSc in Korean.
MATERIALS AND METHODS
Seventy two patients (68 women, 4 men) with SSc fulfill-
ing the criteria proposed by the American College of Rheu-
matology (14) were enrolled. The age at diagnosis was 43.5±
12.6 yr old (mean±SD). The controls were 114 healthy, dis-
ease free Koreans (41 women, 73 men). The age at enrollment
was 37.2±4.6 yr old. The medical records of patients were
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To determine whether angiotensin-converting enzyme (ACE) gene insertion/dele-
tion (I/D) polymorphism is associated with the development and clinical features of
systemic sclerosis (SSc) in Korean, we studied seventy two Korean patients with
SSc fulfilling the ACR preliminary classification criteria. The controls were 114 healthy,
disease free Koreans. ACE I/D genotypes were determined by PCR method using
oligonucleotides. Sixty eight patients (94.4%) were women and age at diagnosis
was 43.5±12.6 yr old (mean±SD). Thirty nine patients (54.2%) had a diffuse type
of SSc. There were no statistical differences in the frequencies of all ACE I/D geno-
types and D allele between patients and controls, and neither between diffuse and
limited types of SSc. ACE I/D gene polymorphism was not associated with the devel-
opment of SSc in Korea. The investigation for the pathogenesis of SSc requires
more studies about the role of other candidate genes such as endothelin, TGF- ,
nitric oxide, or angiotensin II receptor in addition to the ACE genes.
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reviewed retrospectively to collect clinical and laboratory data
at the time of diagnosis and follow up. Anti-topoisomerase
I autoantibody (Anti-topo I) was measured by double immun-
odiffusion (Immunothink, Seoul, Korea) and anti-centromere
autoantibody (ACA) by a characteristic discrete speckled nu-
clear staining pattern on indirect immunofluorescent stains
using IT-1 cell (Immunothink, Seoul, Korea). For ACE geno-
typing, every patient’s genomic DNA was isolated from peri-
pheral blood (Puregene kit, Gentra systems, Minneapolis,
MN, U.S.A.) after getting the written informed consent.
ACE I/D genotype determination
ACE I/D genotype was determined by PCR method using
oligonucleotides (sense 5′ CTGGAGACCACTCCCATCCT
TTCT 3′ , and antisense 5′ GATGTGGCCATCACATTCGT
CAGAT 3′ ). The reaction was carried out using 250 ng of ge-
nomic DNA, 10 mM Tris-HCl, 50 mM KCl, 3 mM MgCl2,
0.5 mM of each dNTP, and 1 unit of Taq DNA polymerase
(Boehringer Mannheim, Germany) at a final volume of 40  L
under the following conditions: 30 cycles of denaturation at
94℃ for 1 min, annealing at 58℃ for 1 min, and extension
at 72℃for 2 min by Gene Amp system 9600 (Perkin Elmer
Biosystem, Norwalk, CT, U.S.A.). The PCR products (190
and 490 bp) were electrophoresed on ethidium bromide sta-
ined 2% agarose gel and visualized under UV transillumina-
tor (GelDoc 2000, Bio-Rad, CA, U.S.A.). On electrophoresis,
ACE genotype I/I showed a 490 bp band, genotype D/D
showed a 190 bp band, and I/D genotype showed both of 490
and 190 bp bands (10). We tried to confirm the genotypes
by modification of PCR; annealing temperature at 60℃, and
addition of the 5% dimethylsulfoxide in reaction mixture
(15). In addition, each DD genotype was subjected to a PCR
with primer pair that recognizes an insertion specific sequence
using same PCR condition with first PCR, except an anneal-
ing temperatue of 67℃to reduce overestimation of DD geno-
type (15).
Statistical analysis
The chi-square test was used for comparison of nonpara-
metric data and Fisher’s exact test was used when the num-
ber was small. For comparison of parametric data, Student’s
t-test was used. The p-value lower than 0.05 (two-tailed) was
considered statistically significant. We employed SPSS for
Windows version 11.0
RESULTS
Clinical characteristics of patients with SSc
All patients had Raynaud phenomenon and the other man-
ifestations were sclerodactyly (87.5%), digital pitting scar
(47.2%), distal phalangeal resorption (29.2%), telangiectasia
(25.0%), and subcutaneous calcinosis (5.6%). Interstitial lung
disease was found in 37 patients (51.4%). Anti-topo I was
positive in 15 patients (20.8%) and ACA in 4 patients (5.6%)
(Table 1).
The diffuse type of SSc was observed in 39 patients (54.2
%), showing more digital pitting scar (odds ratio [OR]=2.875,
95% confidence interval [95% CI]: 1.095-7.545, p=0.030)
and distal phalangeal resorption (OR=5.602, 95% CI: 1.651-
19.015, p=0.004) than the limited type (Table 1). 
Distribution of ACE I/D genotypes in patients with SSc
and controls
The frequencies of II, ID, and DD genotypes were 45.8%,
44.5%, and 9.7% in patients, and 34.2%, 50.0%, and 15.8%
in normal controls, respectively (Table 2). Also the frequency
of D allele was 0.32 in patients, and 0.41 in normal controls.
There was no significant difference in the distribution of geno-
types and alleles between patients and controls. In addition
there was no important difference in the gene frequency bet-
ween diffuse and limited types of SSc. 
Diffuse vs. limited SSc. *OR=2.875, 95% CI: 1.095-7.545, p=0.030. 
� OR=








Raynaud phenomenon 72 (100) 39 (100) 33 (100)
Sclerodactyly 63 (87.5) 37 (94.9) 26 (78.8)
Digital pitting scar 34 (47.2) 23 (59.0)* 11 (33.3)
Distal phalangeal resorption 21 (29.2) 17 (43.6)
� 4 (12.1)
Telangiectasia 18 (25.0) 11 (28.2) 7 (21.2)
Subcutaneous calcinosis 4 (5.6) 3 (7.7) 1 (3.0)
Interstitial lung disease 37 (51.4) 24 (72.7) 13 (39.4)
Anti-topoisomerase I autoantibody15 (20.8) 9 (23.1) 6 (18.2)
Anti-centromere autoantibody 4 (5.6) 1 (2.6) 3 (9.1)
Table 1. Clinical characteristics in patients with systemic sclero-
sis (SSc)
SSc vs. Controls. *II genotype compared with ID and DD genotypes, p
corr=0.226. 
� ID compared with II and DD, p corr=0.920. 
� DD com-
pared with II and ID, p corr=0.474. 
�D allele compared with I allele, p=
0.186. ACE, angiotensin-converting enzyme.
SSc Diffuse SSc  Limited SSc Controls
(n=72) (n=39) (n=33) (n=114)
ACE I/D genotype (%)
II 33 (45.8)* 20 (51.3) 13 (39.4) 39 (34.2)
ID 32 (44.5)
� 16 (41.0) 16 (48.5) 57 (50.0)
DD 7 (9.7)
� 3 (7.7) 4 (12.1) 18 (15.8)
ACE D allele frequency 
D 0.32
� 0.28 0.36 0.41
Table 2. Distribution of ACE I/D genotypes between patients with
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ACE I/D genotypes and clinical features of SSc
There was no significant difference in the frequency of D
allele according to the presence of individual clinical para-
meters of SSc (data not shown).
DISCUSSION
The main pathology of SSc is endothelial dysfunction.
Higher ACE levels, related to the ACE D allele, may promote
the production of angiotensin II and the degradation of bra-
dykinin (16). However the ACE activity, which has been re-
ported in SSc, was rather lower than normal even in those
patients with very early disease, and without pulmonary
hypertension resulting from endothelial dysfunction by
chronic injury (17).
ACE I/D genotypes in 73 Italian patients with SSc and 112
controls showed that ACE D allele was associated with an
increased risk of SSc, but not with the clinical features and
disease subsets (13). In contrast, we did not find an associa-
tion of ACE I/D genotypes with Korean SSc. The diffuse type
of SSc showed more digital pitting scar and distal phalangeal
resorption than limited type, but the distribution of ACE I/D
genotypes was not different between both types. When we
compared the frequencies of genotypes in SSc patients bet-
ween Italian data (13) and ours, the frequency of D allele and
DD genotype was much lower in this study (32% vs. 64%
for D allele, and 9.7% vs. 38% for DD genotype). The exact
reason why two studies showed different result requires more
careful evaluation. Compared with Italian data (13), we have
more women (94% vs. 85%) and younger (mean age, 44 vs.
62) patients. Although, it is still uncertain whether demo-
graphic discrepancy such as age or female predominance may
influence the distribution of ACE I/D genes, there was no
meaningful difference of gene frequency between Korean and
Italian controls despite different sex and age ratios. The fre-
quency of DD genotype, linked to higher ACE level in nor-
mal, was lower than the other genotypes in Korean SSc pa-
tients, but the difference did not show statistical significance.
The exact correlation between ACE I/D genotype and serum
levels of ACE in patients with SSc has not been performed
yet. The exact reason of this discrepancy in the association
with SSc is still unclear, and the racial differences in the genetic
background, or interaction between genes controlling vascu-
lar tone may play a role.
In conclusion, the ACE I/D polymorphism was not asso-
ciated with the development of SSc in Korea. The genetic
susceptibility in SSc needs more studies about the role of the
other candidate genes such as endothelin-1, endothelin recep-
tor, TGF- , nitric oxide, or angiotensin II receptor, in addi-
tion to the ACE genes. 
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